(Reuters) -Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.
Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close.
Point Biopharma’s shares soared 84% in premarket trading.
The companies expect the deal to close by the end of 2023.
Source: Read Full Article